| Year |
Citation |
Score |
| 2022 |
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CWM, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, ... ... Oak JS, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. PMID 36584673 DOI: 10.1016/j.ccell.2022.12.005 |
0.444 |
|
| 2021 |
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. PMID 34312556 DOI: 10.1038/s41591-021-01436-0 |
0.302 |
|
| 2020 |
Baird JH, Frank MJ, Craig J, Patel S, Spiegel JY, Sahaf B, Oak JS, Younes S, Ozawa M, Yang E, Natkunam Y, Tamaresis JS, Ehlinger Z, Reynolds WD, Arai S, et al. CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. PMID 33512414 DOI: 10.1182/blood.2020009432 |
0.357 |
|
| 2020 |
Schultz L, Patel S, Davis KL, Ramakrishna S, Sahaf B, Bhatia N, Baggott C, Erickson C, Majzner RG, Oak J, Bertaina A, Mackall C, Feldman S. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. Journal For Immunotherapy of Cancer. 8. PMID 32929049 DOI: 10.1136/Jitc-2020-001073 |
0.357 |
|
| 2020 |
Tsai AG, Glass DR, Juntilla M, Hartmann FJ, Oak JS, Fernandez-Pol S, Ohgami RS, Bendall SC. Multiplexed single-cell morphometry for hematopathology diagnostics. Nature Medicine. 26: 408-417. PMID 32161403 DOI: 10.1038/s41591-020-0783-x |
0.316 |
|
| 2019 |
Schultz LM, Patel S, Ramakrishna S, Bertaina A, Bhatia N, Oak J, Majzner RG, Baggott C, Davis KL, Mackall CL, Feldman SA. Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction Blood. 134: 4471-4471. DOI: 10.1182/Blood-2019-129436 |
0.377 |
|
| 2019 |
Kumar J, Scott G, Oak J, Raess P, Gratzinger D. Flow Cytometry Signature for Kikuchi-Fujimoto/Lupus Lymphadenitis Derived From 975 Benign and Malignant Lymphadenopathies American Journal of Clinical Pathology. 152: S105-S106. DOI: 10.1093/Ajcp/Aqz121.004 |
0.317 |
|
| 2018 |
Oak J, Spiegel JY, Sahaf B, Natkunam Y, Long SR, Hossain N, Mackall CL, Kong KA, Miklos DB. Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy Blood. 132: 4656-4656. DOI: 10.1182/BLOOD-2018-99-120206 |
0.387 |
|
| 2018 |
Spiegel JY, Sahaf B, Hossain N, Frank MJ, Claire G, Abramian M, Latchford T, Villa B, Cancilla J, Oak J, Natkunam Y, Long SR, Arai S, Johnston LJ, Lowsky R, et al. Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma Blood. 132: 576-576. DOI: 10.1182/Blood-2018-99-113261 |
0.322 |
|
| 2018 |
Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S, Mavroukakis S, Oak J, Natkunam Y, Meyer EH, Frank MJ, Feldman SA, Long SR, Qin H, Fry TJ, et al. Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies Blood. 132: 490-490. DOI: 10.1182/Blood-2018-99-110142 |
0.307 |
|
| 2013 |
So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/Jbc.M112.379446 |
0.717 |
|
| 2013 |
Tirotta E, Duncker P, Oak J, Klaus S, Tsukamoto MR, Gov L, Lane TE. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. Journal of Neuroimmunology. 254: 110-6. PMID 23102608 DOI: 10.1016/J.Jneuroim.2012.10.005 |
0.401 |
|
| 2012 |
Soyfoo MS, Konno A, Bolaky N, Oak JS, Fruman D, Nicaise C, Takiguchi M, Delporte C. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren's syndrome? Oral Diseases. 18: 568-74. PMID 22320885 DOI: 10.1111/J.1601-0825.2012.01909.X |
0.526 |
|
| 2009 |
Oak JS, Chen J, Peralta RQ, Deane JA, Fruman DA. The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 42: 447-58. PMID 19811262 DOI: 10.1080/08916930902911746 |
0.775 |
|
| 2009 |
Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase (Proceedings of the National Academy of Sciences of the United States of America (2009) 103, 45, (16882-16887) 10.1073/pnas. 0607984103) Proceedings of the National Academy of Sciences of the United States of America. 106: 10871. DOI: 10.1073/Pnas.0905401106 |
0.726 |
|
| 2008 |
de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 180: 6518-26. PMID 18453570 DOI: 10.4049/Jimmunol.180.10.6518 |
0.735 |
|
| 2007 |
Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochemical Society Transactions. 35: 1109-13. PMID 17956290 DOI: 10.1042/Bst0351109 |
0.706 |
|
| 2007 |
Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 40: 433-41. PMID 17729037 DOI: 10.1080/08916930701464780 |
0.749 |
|
| 2007 |
Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 109: 2894-902. PMID 17164340 DOI: 10.1182/Blood-2006-07-038620 |
0.759 |
|
| 2006 |
Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America. 103: 16882-7. PMID 17071741 DOI: 10.1073/Pnas.0607984103 |
0.749 |
|
| 2004 |
Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman DA. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. European Journal of Immunology. 34: 2968-76. PMID 15384044 DOI: 10.1002/Eji.200425326 |
0.776 |
|
| Show low-probability matches. |